313 related articles for article (PubMed ID: 17486110)
1. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.
Galvão DA; Taaffe DR; Spry N; Newton RU
Prostate Cancer Prostatic Dis; 2007; 10(4):340-6. PubMed ID: 17486110
[TBL] [Abstract][Full Text] [Related]
2. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.
Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
J Clin Oncol; 2010 Jan; 28(2):340-7. PubMed ID: 19949016
[TBL] [Abstract][Full Text] [Related]
3. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.
Segal RJ; Reid RD; Courneya KS; Malone SC; Parliament MB; Scott CG; Venner PM; Quinney HA; Jones LW; D'Angelo ME; Wells GA
J Clin Oncol; 2003 May; 21(9):1653-9. PubMed ID: 12721238
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
5. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review.
Bylow K; Mohile SG; Stadler WM; Dale W
Cancer; 2007 Dec; 110(12):2604-13. PubMed ID: 17960609
[TBL] [Abstract][Full Text] [Related]
6. Osteoporosis risk and interest in strength training in men receiving androgen ablation therapy for locally advanced prostate cancer.
Ott C; Fulton MK
J Am Acad Nurse Pract; 2005 Mar; 17(3):113-22. PubMed ID: 15748224
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure.
Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
Prostate Cancer Prostatic Dis; 2009; 12(3):233-40. PubMed ID: 19488067
[TBL] [Abstract][Full Text] [Related]
8. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
Gomella LG
BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
[TBL] [Abstract][Full Text] [Related]
9. Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response.
Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
J Urol; 2011 Oct; 186(4):1291-7. PubMed ID: 21849187
[TBL] [Abstract][Full Text] [Related]
10. A holistic approach to androgen deprivation therapy: treating the cancer without hurting the patient.
Tombal B
Urol Int; 2009; 83(4):373-8. PubMed ID: 19996641
[TBL] [Abstract][Full Text] [Related]
11. Metabolic and cardiovascular effects of androgen deprivation therapy.
Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
[TBL] [Abstract][Full Text] [Related]
12. Bone health in men receiving androgen deprivation therapy for prostate cancer.
Eastham JA
J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
[TBL] [Abstract][Full Text] [Related]
13. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
[TBL] [Abstract][Full Text] [Related]
14. Complications of androgen deprivation therapy in prostate cancer.
Schwandt A; Garcia JA
Curr Opin Urol; 2009 May; 19(3):322-6. PubMed ID: 19318949
[TBL] [Abstract][Full Text] [Related]
15. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
Singer EA; Golijanin DJ; Messing EM
Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
[TBL] [Abstract][Full Text] [Related]
17. Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
Harle LK; Maggio M; Shahani S; Braga-Basaria M; Basaria S
Clin Adv Hematol Oncol; 2006 Sep; 4(9):687-96. PubMed ID: 17099626
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
Basaria S
J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
[TBL] [Abstract][Full Text] [Related]
19. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
Israeli RS; Ryan CW; Jung LL
J Urol; 2008 Feb; 179(2):414-23. PubMed ID: 18076933
[TBL] [Abstract][Full Text] [Related]
20. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
